1-12 of 12
Beenish S. Manzoor
Close
Sort by
Journal Articles

Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study

Clinical Trials & Observations
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael J Hallek, Kirsten Fischer
Journal: Blood
Blood blood.2024024631.
https://doi.org/10.1182/blood.2024024631
Published: 2024
Includes: Supplemental data
Journal Articles

Patient Preferences for Fixed Versus Treat-to-Progression Therapies in Chronic Lymphocytic Leukemia

Arliene Ravelo, Kelley Myers, Claire Ervin, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S Manzoor, Juliana M. L. Biondo, Carol Mansfield
Journal: Blood
Blood (2023) 142 (Supplement 1): 3706.
https://doi.org/10.1182/blood-2023-174719
Published: 2023
Journal Articles

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Beenish S Manzoor, Scott F. Huntington, Dureshahwar Jawaid, Justin T. Puckett, Nnadozie Emechebe, Arliene Ravelo, Sachin Kamal-Bahl, Jalpa A. Doshi
Journal: Blood
Blood (2023) 142 (Supplement 1): 5085.
https://doi.org/10.1182/blood-2023-177939
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments

Arliene Ravelo, Kelley Myers, Robyn Brumble, Cooper Bussberg, Brian Koffman, Beenish S. Manzoor, Juliana Biondo, Carol Mansfield
Journal: Blood
Blood (2022) 140 (Supplement 1): 10803–10805.
https://doi.org/10.1182/blood-2022-159648
Published: 2022
Journal Articles

Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France

Honghao Fang, Harinala Ravonimbola, Nisha C Hazra, Zhou Zhou, MS, Beenish S. Manzoor, PhD MPH, Vincent Levy, MD PhD, Loic Ysebaert, MD PhD, Nathanael Kabore, Kavita Sail
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
https://doi.org/10.1182/blood-2020-137034
Published: 2020
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada

Anuja Chatterjee, MSc, Gijs Van de Wetering, PhD, Ron Goeree, Anne Marie Desbois, Patricia Manzi, MSc, BPharm, Beenish S Manzoor, PhD, Carolyn Owen, MDFRCPC, Kavita Sail, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-134596
Published: 2020
Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Dandan Zheng, Kavita Sail, PhD, Lindsey E Roeker, MD, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Toby A. Eyre, Alan Skarbnik, MD, Rajat Bannerji, MDPhD, Barbara Eichhorst, MD, Danielle M. Brander, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Rajesh Kamalakar, MS, Nnadozie Emechebe, MPH, Irina Pivneva, Rebecca Burne, Annie Guerin, MSc, Matthew S. Davids, MD, Anthony Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–22.
https://doi.org/10.1182/blood-2020-134676
Published: 2020
Journal Articles

Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen

Meghan C. Thompson, MD, John N. Allan, MD, Kavita Sail, PhD, Beenish S. Manzoor, PhD MPH, Jeffrey J. Pu, MD PhD, Paul M. Barr, MD, Catherine C. Coombs, MD, Stephen J. Schuster, MD, Alan Skarbnik, MD, Joanna M Rhodes, MD, Jacqueline C. Barrientos, MD, Lindsey E Roeker, MD, Lori A. Leslie, MD, Manali Kamdar, MD, Michael Y. Choi, MD, Martin Simkovic, MD PhD, Frederick Lansigan, MD, Brittany Jane Hale, MD, Andrew D Zelenetz, MD PhD, Alison J. Moskowitz, MD, Kurt S. Bantilan, MPH, Celina J. Komari, BS, Andre H. Goy, MD, Tatyana A. Feldman, MD, Richard R. Furman, MD, Anthony R. Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-138725
Published: 2020
Journal Articles

Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies

Anthony R. Mato, MDMSCE, Kavita Sail, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Mazyar Shadman, MD MPH, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Nicole Lamanna, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1756.
https://doi.org/10.1182/blood-2019-124600
Published: 2019
Journal Articles

Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study

Mazyar Shadman, MD MPH, Kavita Sail, PhD, Beenish S Manzoor, PhD, Maryam Sarraf Yazdy, MD, Brian T. Hill, MD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Nnadozie Emechebe, MPH, Rajesh Kamalakar, MS, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Thomas Marshall, PharmD, MS, Jacqueline Nielsen, PhD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Anna Schuh, PhD, Toby A. Eyre, MD, Nicole Lamanna, MD, William G. Wierda, MD PhD, Alan Skarbnik, MD, Lindsey E. Roeker, MD, Rajat Bannerji, MD PhD, James M. Pauff, MD PhD, Stephen J. Schuster, MD, George A Follows, MD PhD, Bruce D. Cheson, MD, Barbara F. Eichhorst, MD, Danielle M. Brander, MD, Irina Pivneva, PhD, Annie Guerin, MSc, Anthony R. Mato, MDMSCE
Journal: Blood
Blood (2019) 134 (Supplement_1): 3048.
https://doi.org/10.1182/blood-2019-131401
Published: 2019
Journal Articles

Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids, MD, Anuja Chatterjee, MSc, Arliene Ravelo, MPH, Sheila Shapouri, PharmD, MS, Beenish S Manzoor, PhD, Kavita Sail, PhD, Gijs Van de Wetering, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 4741.
https://doi.org/10.1182/blood-2019-123706
Published: 2019